Phase II sequential treatment trial of single agent Nivolumab, then combination Ipilumumab + Nivolumab in metastic or unresectable non-clear cell renal cell carcinoma (ANZUP1602). UNISoN.
- Pook, David (Primary Chief Investigator (PCI))
Project: Research